Sydney, Oct 24, 2006 (ABN Newswire) - Life Therapeutics (ASX: LFE)(PNK: LFEFY) has signed a new two year contract to produce hyperimmune plasma for a major fractionator. The value of the contract ranges from a minimum of A$4M up to A$12M per year for two years.
"This contract signals our further shift to producing the high-margin, hyperimmune plasma, which will further enhance our product mix," said Dr. Hari Nair, CEO and President of Life Therapeutics. "These types of high-margin products are what our company excels in producing and what our entire production system is geared to accomplish."
As previously advised, Life Therapeutics recently installed a new donor computer system company-wide to increase processing and aid production of hyperimmune and normal source plasma. This will further reduce the cost of product management and improve the order fulfilment process.
"This contract signals our further shift to producing the high-margin, hyperimmune plasma, which will further enhance our product mix," said Dr. Hari Nair, CEO and President of Life Therapeutics. "These types of high-margin products are what our company excels in producing and what our entire production system is geared to accomplish."
As previously advised, Life Therapeutics recently installed a new donor computer system company-wide to increase processing and aid production of hyperimmune and normal source plasma. This will further reduce the cost of product management and improve the order fulfilment process.
| Tweet |
About Life Therapeutics Limited
Life Therapeutics is an international company that specializes in niche therapeutic hyperimmune products. It has 14 operational plasma collection centers and signed leases for a further 2 centers around the US. The Company has considerable experience recruiting and collecting hard to find hyperimmune plasma for IND studies and clinical trials. Life Therapeutics has 500 employees, located in the United States and 14 plasma donor centers in eight American States. It has an established U.S. American Depositary Receipt (ADR) Level I program, which enables trading in Life Therapeutics shares by U.S. based investors. The company's divisions are all headquartered in Atlanta, Georgia.
 |
Related Companies |
>>> Life Therapeutics Limited |
| |
Related Industry Topics: |
Biotech | Health & Pharm General | |
| |
This Page Viewed: (Last 30 Days: 100) (Since Published: 14280) |
Events & Exhibitions
|
Site Search
| ENGLISH All Languages |
Upcoming WebCasts
 | Mr Mark Paton CEO Cue Energy Resources Tuesday, June 12, 2012 |
 | Mr Alan Hopkins CEO Pan Asia Corporation Tuesday, June 12, 2012 |
 | Mr Barry Dawes Martin Place Securities Tuesday, June 12, 2012 |
 | Dr Andrea Grant CEO Living Cell Technologies Monday, July 02, 2012 |
Companies in the News
Mobile Video TV
|
||
|
||
